* Exploding Onto Investor's Radar Screens: Smallcap Alert
@ 2004-08-17 12:20 Jeanne Fischer
0 siblings, 0 replies; only message in thread
From: Jeanne Fischer @ 2004-08-17 12:20 UTC (permalink / raw)
The Growth Stock Report
Breaking News!!
Genex Pharmaceuticals (OTCBB: GENX.OB) EARNINGS RELEASE:
Genex Pharmaceutical 2nd Quarter Revenue Up 432%.
Gross PR0FIT Up 380% as Genex's Net INC0ME Soars.
Sees Continued Earnings Momentum for Remainder of 2004.
______________________________________________________
Monday August 16, 9:28 am ET
NEW YORK-- (BUSINESS WIRE) --Aug.16, 2004 -- Genex Pharmaceutical, Inc.
(Stock Symbol: GENX.OB) announced financial results for its second
quarter ending June 30, 2004.
The following are some of the highlights in its recent quarterly filing
with the SEC:
432% in-crease in revenue for Q2 2004 compared to Q2 2003.
874% in-crease in revenue for 6 months ended June 30, 2004 compared to
same period last year.
Significant in-crease in net INC0ME for Q2 2004 compared to Q2 2003 and
for the 6 month period ended June 30, 2004 as compared to same period
last year.
380% in-crease in Gross PR0FIT for Q2 2004 compared to Q2 2003.
840% in-crease in Gross PR0FIT for 6 months ended June 30, 2004
compared to same period last year.
______________________________________________________
REVENUE
For the three month period ended June 30, 2004 as compared to the three
month period ended June 30, 2003, Genex generated net revenues of
$525,750 and $98,763, respectively, reflecting an in-crease of $426,987
or 432%. The in-crease in revenues was primarily attributable to the
commercialization of the company's main product, RBX, as well as
in-creased marketing efforts, which resulted in in-creases in our
customer base and related volume of recurring and new customer sales.
For the six month period ended June 30, 2004 as compared to the period
ended June 30, 2003, Genex generated net revenues of $961,958 and
$98,763, respectively, reflecting an in-crease of $863,195 or 874%. The
in-crease in revenues was primarily attributable to the
commercialization of the company's main product, RBX, as well as
in-creased marketing efforts, which resulted in in-creases in our
customer base and related volume of recurring and new customer sales.
______________________________________________________
NET INC0ME
The company's net INC0ME was $218,595 for the six months ended June 30,
2004, an in-crease of $242,524 compared to $(23,929) for the period
ended June 30, 2003. The in-crease is attributed to the substantial
growth in the demand for our products throughout China and continued
development and implementation of our business during 2004.
Net INC0ME was $151,904 for the three months ended June 30, 2004, an
in-crease of $175,833 compared to ($23,929) for the three months ended
June 30, 2003. The in-crease is attributed to the substantial growth in
the demand for the Company's products throughout China and continued
development and implementation of our business during 2004.
______________________________________________________
GROSS PR0FIT
Genex achieved a gross PR0FIT of $758,040 for the six months ended June
30, 2004, an in-crease of $677,403 or 840%, compared to $80,637 for the
period ended June 30, 2003. Gross margin, as a percentage of revenues,
decreased from 82% for the six months ended June 30, 2003, to 79% for
the period ended June 30, 2004. The decrease in gross margin was
primarily attributable to commercialization of the company's main
product, RBX, and in-creased sales of products.
Genex achieved a gross PR0FIT of $386,750 for the three months ended
June 30, 2004, an in-crease of $306,113 or 380%, compared to $80,637 for
the three months ended June 30, 2003. Gross margin, as a percentage of
revenues, decreased from 82% for the three months ended June 30, 2003,
to 74% for the three months ended June 30, 2004. The decrease in gross
margin was primarily attributable to commercialization of the Company's
main product, RBX, and in-creased sales of products.
"We are seeing significant in-creases in revenues and PR0FITABILITY as
we respond to growing customer demand for RBX. We see continued earnings
momentum for the remainder of 2004," said Chairman and Chief Executive
Mr. Fuzhi Song.
______________________________________________________
About Genex Pharmaceutical, Inc.
Genex Pharmaceutical, Inc. is a biomedical technology company with
distinctive proprietary technology for an orthopedic device that treats
bone-related injuries. Headquartered in Tianjin, China, the Company
manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400
hospitals in 22 provinces throughout mainland China. RBX is approved by
the State Food and Drug Administration (SFDA) in China (the Chinese
government agency that regulates drugs and medical devices). RBX offers
a modern alternative to traditional methods of treating orthopedic
injuries.
Good Luck and Succesful Trading. Go GENEX!!
______________________________________________________
DISCL-AIMER: Information within this em-ail contains "F0RWARD looking
statements" within the meaning of Section 27A of the Securities Act of
1933 and Section 21B of the Securities Exchange Act of 1934. Any
statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not statements of
historical fact and may be "F0RWARD looking statements."F0RWARD looking
statements are based on expectations, estimates and projections at the
time the statements are made that involve a number of risks and
uncertainties which could cause actual results or events to differ
materially from those presently anticipated. F0RWARD looking statements
in this action may be identified through the use of words such as
"projects", "foresee", "expects", "will," "anticipates," "estimates,"
"believes," "understands" or that by statements indicating certain
actions "may," "could," or "might" occur. As with many micro-cap stocks,
today's company has additional risk factors worth noting. Those factors
include:a limited operating history, the company advancing cash to
related parties and a shareholder on an unsecured basis: one vendor, a
related party through a majority stockholder, supplies ninety-seven
percent of the company's raw materials: reliance on two customers for
over fifty percent of their business and numerous related party
transactions and the need to raise capital.These factors and others are
more fully spelled out in the company's SEC filings. We urge you to read
the those filings before you invest. The Growth ST0CK Report does not
represent that the information contained in this message states all
material facts or does not omit a material fact necessary to make the
statements therein not misleading. All information provided within this
em-ail pertaining to investing, ST0CKS, securities must be understood as
information provided and not investment advice. The Growth ST0CK Report
advises all readers and subscribers to seek advice from a registered
professional securities representative before deciding to trade in
ST0CKS featured within this ema-il. None of the material within this
report shall be construed as any kind of investment advice or
solicitation.Many of these companies are on the verge of bankruptcy. You
can lose all your M0NEY by investing in this ST0CK. The publisher of The
Growth ST0CK Report is not a registered investment ADVIS0R. Subscribers
should not view information herein as legal, tax, accounting or
investment advice. Any reference to past performance(s) of companies are
specially selected to be referenced based on the favorable performance
of these companies. You would need perfect timing to acheive the results
in the examples given. There can be no assurance of that happening.
Remember, as always, past performance is never indicative of future
results and a thorough due diligence effort, including a review of a
company's filings, should be completed prior to investing. In compliance
with the Securities Act of 1933, Section 17(b),The Growth ST0CK Report
discloses the receipt of twelve thousand D0LLARS from a third party
(DMI,Inc.), not an officer, director or affiliate shareholder for the
circulation of this report. DMI, Inc. has a position in the ST0CK they
will sell at any time without notice. Be aware of an inherent conflict
of interest resulting from such compensation due to the fact that this
is a paid adver-tisement and we are conflicted. All factual information
in this report was gathered from public sources, including but not
limited to Company Websites, SEC Filings and Company Press Releases. The
Growth ST0CK Report believes this information to be reliable but can
make no guarantee as to its accuracy or completeness. Use of the
material within this em-ail constitutes your acceptance of these terms.
_______________________________________________
Guile-user mailing list
Guile-user@gnu.org
http://lists.gnu.org/mailman/listinfo/guile-user
^ permalink raw reply [flat|nested] only message in thread
only message in thread, other threads:[~2004-08-17 12:20 UTC | newest]
Thread overview: (only message) (download: mbox.gz follow: Atom feed
-- links below jump to the message on this page --
2004-08-17 12:20 Exploding Onto Investor's Radar Screens: Smallcap Alert Jeanne Fischer
This is a public inbox, see mirroring instructions
for how to clone and mirror all data and code used for this inbox;
as well as URLs for read-only IMAP folder(s) and NNTP newsgroup(s).